Fulcrum Therapeutics, INC Form 4 insider transactions

Kevin Tang and 1 other reported changes in beneficial ownership of Fulcrum Therapeutics, Inc. common stock on July 16, 2026.

Kevin Tang and 1 other reported changes in beneficial ownership of Fulcrum Therapeutics, Inc. common stock on July 13, 2026.

Fulcrum Therapeutics Director Katina Dorton acquired 32,000 stock options with an exercise price of $3.66, vesting on June 30, 2026.

Robert J. Gould, a Director at Fulcrum Therapeutics, Inc., acquired 32,000 stock options on June 30, 2026, as detailed in a recent SEC Form 4 filing.

Fulcrum Therapeutics Director Kate Haviland acquired stock options for 32,000 shares of common stock.

Fulcrum Therapeutics Director Rachel King acquired 32,000 stock options with an exercise price of $3.66, vesting on June 30, 2026.

Director James A. Geraghty of Fulcrum Therapeutics, Inc. acquired stock options for 32,000 shares, with vesting contingent on continued service.

Director Joshua Lehrer-Graiwer was granted 64,000 stock options in Fulcrum Therapeutics, Inc. as part of a standard equity incentive.

Fulcrum Therapeutics Director Robert J. Gould filed an amended Form 4 to correct the weighted average price of a 15,000-share stock sale.

Fulcrum Therapeutics' Chief Financial Officer, Alan A Musso, was granted 170,000 stock options with an exercise price of $10.72.

Fulcrum Therapeutics' Chief Legal Officer, Curtis Gale Oltmans, was granted 170,000 stock options with an exercise price of $10.72, vesting over four years.

Fulcrum Therapeutics Director Robert J. Gould sold 15,000 shares of common stock for approximately $10.72 per share under a pre-arranged trading plan.

Fulcrum Therapeutics' Principal Accounting Officer, Greg Tourangeau, was granted 57,000 stock options with an exercise price of $10.72.

Fulcrum Therapeutics' President and CEO, Alex Sapir, was granted 650,000 stock options with an exercise price of $10.72, vesting over four years.

Fulcrum Therapeutics Director Robert J. Gould sold 15,000 shares of common stock for a weighted average price of $11.8726, reducing his direct beneficial ownership to 469,864 shares.

Fulcrum Therapeutics' Chief Legal Officer, Curtis Gale Oltmans, sold 3,452 shares of common stock for $12.92 per share as part of a pre-arranged trading plan.

RA Capital Management, a 10% owner and director, reported significant sales of Fulcrum Therapeutics common stock totaling over 4.1 million shares.

Robert J. Gould, a Director at Fulcrum Therapeutics, Inc., reported the sale of 15,000 shares of common stock at a weighted average price of $11.033 per share.

Fulcrum Therapeutics, Inc. Director Sonja Banks was granted 36,000 stock options with an exercise price of $7.38, vesting over one year subject to continued service.

Fulcrum Therapeutics, Inc. Director Robert J. Gould was granted 36,000 stock options with an exercise price of $7.38 per share, aligning his interests with long-term shareholder value.

Fulcrum Therapeutics, Inc. Director Alan Ezekowitz was granted 36,000 stock options with an exercise price of $7.38, vesting over one year.

Fulcrum Therapeutics, Inc. Director James A. Geraghty was granted 36,000 stock options with an exercise price of $7.38 per share, vesting over one year.

Fulcrum Therapeutics, Inc. Director Katina Dorton was granted 36,000 stock options with an exercise price of $7.38, aligning her interests with shareholder value.

Fulcrum Therapeutics, Inc. Director Kate Haviland was granted 36,000 stock options with an exercise price of $7.38, vesting on the first anniversary of the grant date or earlier.

Fulcrum Therapeutics, Inc. director Colin Hill was granted 36,000 stock options with an exercise price of $7.38 per share, vesting over one year.

Rachel K. King, a Director at Fulcrum Therapeutics, Inc., was granted 36,000 stock options with an exercise price of $7.38, vesting over one year.

Gregory Tourangeau, Principal Accounting Officer of Fulcrum Therapeutics, sold 498 shares of common stock on May 8, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Alan Musso, CFO of Fulcrum Therapeutics, reports the grant of stock options.

Alex Sapir, President & CEO of Fulcrum Therapeutics, was granted stock options to purchase 582,000 shares of common stock on January 24, 2025.

Gregory Tourangeau, Principal Accounting Officer of Fulcrum Therapeutics, acquired stock options on January 24, 2025.